Page last updated: 2024-10-26

etilefrine and Liver Cirrhosis

etilefrine has been researched along with Liver Cirrhosis in 1 studies

Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.

Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Research Excerpts

ExcerptRelevanceReference
"Ninety cirrhotic patients with ascites were studied after administration of HSS infusion (n=25) or etilefrine tablets (n=25), or both (n=25) plus standard diuretics therapy (SDT), or SDT alone (n=15)."8.12Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites. ( Badra, G; El-Haggar, S; El-Said, H; Ibrahim, O; Radwan, H, 2022)
"Ninety cirrhotic patients with ascites were studied after administration of HSS infusion (n=25) or etilefrine tablets (n=25), or both (n=25) plus standard diuretics therapy (SDT), or SDT alone (n=15)."4.12Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites. ( Badra, G; El-Haggar, S; El-Said, H; Ibrahim, O; Radwan, H, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Radwan, H1
Ibrahim, O1
Badra, G1
El-Said, H1
El-Haggar, S1

Other Studies

1 other study available for etilefrine and Liver Cirrhosis

ArticleYear
Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites.
    European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:18

    Topics: Aldosterone; Ascites; Biomarkers; C-Reactive Protein; Creatinine; Diuretics; Etilefrine; Furosemide;

2022